The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

Big Pharma hates the telehealth startup. Meme-stock day traders love it. Why CEO Andrew Dudum won’t stop selling GLP-1s, no ...

We recently published Market on Mute? Not for These 10 Stocks With Surprising Gains. Hims & Hers Health, Inc. (NYSE:HIMS) is ...

Hims & Hers Health will continue offering low-cost compounded weight-loss shots even after Novo Nordisk terminated their partnership over alleged “deceptive marketing,” CEO Andrew Dudum said in his ...

Hims & Hers Health is a top telehealth company with strong growth, innovation, and global expansion plans. See more on HIMS ...

Investing.com -- Hims & Hers CEO Andrew Dudum has shared new information about the company’s terminated partnership with Novo Nordisk (NYSE: NVO ), which ended in June 2025, in an interview with The ...

Hims & Hers Health delivered a first quarter that surpassed Wall Street’s expectations, driven by strong adoption of its ...

Investors, CEOs and commentators trashed Hims & Hers founder and CEO Andrew Dudum on social media Wednesday after he praised the "moral courage" of the anti-Israel protesters creating havoc on ...

Andrew Dudum is a disrupter. In 2017 he founded Hims & Hers (NYSE: HIMS), a digital health startup with the goal of upending the traditional healthcare market.

Kevin O'Leary sounded off on Hims & Hers CEO Andrew Dudum over his initial support of the anti-Israel protests and said he would have been fired in seconds if he worked for him.

Andrew Dudum, the Palestinian American CEO of Hims, a telehealth and online pharmacy known for its suggestive New York City subway ads, shared a link to current openings and encouraged the student ...